Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab (Q34585078)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Kazunao Kondo

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Kazuo Umemura

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

187-195

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Safe use of platelet GP IIb/IIIa inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tirofiban. A review of its use in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Newer antiplatelet agents in acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tirofiban--an overview of the phase III trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The platelet membrane glycoprotein IIb-IIIa complex.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo studies on the metabolism of tirofiban

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonenzymatic glycation of human blood platelet proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between fibrinogen binding to human platelets and platelet aggregability

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11929319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003088-200241030-00003

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34585078&oldid=2196829852"